Sai Life Sciences Limited — PPTs, 14-05-2025: Investor Presentation

1. Financial Highlights:

Sai Life Sciences reported revenue growth of 16% to ₹1,695 Cr with a 25% EBITDA margin. Profit after tax jumped 105% to ₹425 Cr, aided by lower finance costs and operating leverage. Material margins improved to 73%. Sustained capex of ₹408 Cr supported manufacturing and discovery expansion. The company’s balance sheet strengthened considerably, with ₹720 Cr debt repaid and net debt turning negative. ROCE rose to 12.3%, while working capital days fell to 117, indicating operational efficiency.

2. Strategic Initiatives & Growth Drivers:

The new Peptide Research Centre enhances capabilities in complex peptide synthesis and conjugation. Investments are focused on expanding R&D and manufacturing capacity, automation, digitalization, and emerging modalities like ADCs, TPDs, CGTs, and oligonucleotides. Efforts to deepen client engagement via integrated CRDMO solutions across the drug development lifecycle continue, supported by capex aimed at expanding global footprints, primarily in India.

3. Business Developments:

Sai Life partners with 300+ innovator clients, including 18 of the top 25 global pharma firms. Discovery service revenue reached ₹626 Cr and CMC revenue ₹1,068 Cr, reflecting robust growth. Over 65% of projects span discovery through manufacturing, showcasing strong program integration. Expansion of delivery facilities in the UK, US, and China supports multi-region client servicing.

4. Market Position & Competitive Advantage:

Sai Life stands out among Asian CRDMOs with 25+ years’ experience, strong scientific expertise, and quality systems aligned with USFDA and PMDA standards. Its integrated platform and scale, alongside sustainability credentials (EcoVadis Silver, UN Global Compact), provide differentiated execution capabilities and stable client relationships in complex chemistries and novel modalities.

5. Investor Implications:

Strong revenue and margin growth combined with a deleveraged balance sheet underline positive growth potential. Focused investments in advanced capabilities and the peptide center position Sai Life well to capitalize on next-gen therapeutic demand. Robust client partnerships and operational efficiencies reduce execution risk, making it an attractive play in India’s expanding CRDMO space serving global innovators.